A myeloablative fractionated busulfan conditioning regimen with sorafenib for alloSCT in AML

109 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Uday Popat, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of a Phase I/II study (NCT03247088) investigating a myeloablative fractionated busulfan conditioning regimen with sorafenib prior to allogeneic stem cell transplant (alloSCT) in patients with acute myeloid leukemia (AML). Prof. Popat highlights that the efficacy of this regimen was encouraging, with a progression-free survival (PFS) rate of 77.8% at one year and 68% at two years and beyond, as well as a two-year overall survival (OS) rate of 74.9%. A multivariate analysis revealed that measurable residual disease (MRD) positivity was the only predictive factor for OS and PFS in this cohort of patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo